Iktos

Generative deep learning is the product across all three named systems. Makya generates de novo molecules under multi parametric optimization constraints, Spaya performs retrosynthesis to convert target compounds into commercially available starting materials, and Ilaka orchestrates the resulting workflow. The design claim is specific rather than generic: the generative model is trained on millions of reactions and builds synthetic accessibility into generation by working from commercial building blocks and organic reactions, rather than generating freely and filtering for feasibility afterwards. The robotics layer exists to execute what the models design.

Meaningful autonomy exists at the execution layer rather than the decision layer. Ilaka is described as taking over the workflow from ordering raw materials through directing synthesis campaigns and robotic chemistry, which is genuine hands off operation, but the objects being automated are laboratory tasks rather than decisions affecting a patient. Design direction stays with chemists, and the platform's stated positioning as built by chemists for chemists reinforces that. Held at B because no confidence thresholds, failure rates or documented human approval gates were located, so the boundary between what the system decides and what a chemist decides is described rather than specified.

More specific than marketing but short of independently verifiable. Disclosed detail includes the generative deep learning basis, training on millions of reactions, an explored chemical space stated at the order of ten to the twenty seventh, synthesis constraints imposed during generation, and published descriptions of newer generative models that design molecules and their three dimensional poses directly from a known active ligand without docking, rigid superposition or conformer enumeration. Held at B because no peer reviewed methods paper establishing core platform performance was located in this review and no model cards or benchmark documentation were found, so the accuracy claims cannot be independently checked.

Adoption is substantial and evidence is thin, which is precisely the pattern this index grades down. The company reports validation through more than 50 and by some accounts more than 60 academic and industrial collaborations, with named partners including Pfizer, Janssen, Merck KGaA, Servier, Sanofi, Ono, Teijin, Galapagos, Chiesi and UCB. That is real commercial traction and a meaningful signal that sophisticated medicinal chemistry organizations find the tools useful. It is not evidence of benefit. No published outcome study, controlled comparison against conventional design, or disclosed clinical stage asset attributable to the platform was located, and the claim that the integrated approach shortens discovery to under two years is vendor stated. Applying the index precedent that scale of use does not substitute for evidence, this sits at C until an outcome is published.

Not applicable in the provider sense and rated accordingly rather than penalized. The platform operates on chemical structures, reaction data and assay results, with no patient data in the workflow. The stewardship question that does matter here is protection of customer chemistry, and unusually for this category it is answered architecturally rather than contractually.

Not applicable. Customers are pharmaceutical and biotechnology medicinal chemistry organizations licensing design software or entering discovery collaborations, not covered entities transferring protected health information.

No SOC 2, ISO 27001 or equivalent attestation was located and no trust center was found. The mitigating factor is structural rather than attested: because the software can be installed on customer premises or inside the customer's own virtual private cloud, a security conscious buyer can remove the vendor from the trust boundary entirely instead of relying on a certification. That option is not available with the partnership only platforms in this category.

Nothing to assess rather than something assessed poorly. The platform is design software and is not a regulated medical device, correctly, and the company does not maintain a disclosed proprietary clinical pipeline of its own. Regulatory standing for molecules designed with these tools sits with the partner that owns the asset, and partner assets are not publicly attributed to the platform, so no asset level regulatory record is available to grade.

No AI governance framework or bias disclosure was located. The domain relevant question is whether a generative model trained on historical reaction data biases output toward familiar chemistry, which would tend to produce molecules that are easy to make and close to known space rather than genuinely novel. The company's synthetic accessibility by design approach makes this tension explicit in the architecture without addressing it as a disclosed limitation, and novelty against training distribution is not reported.

Not applicable in the provider sense, with no EHR touchpoint or clinical workflow surface. The research equivalent is better than most peers: Makya can be driven through a graphical interface designed for medicinal chemists or operated as a Python package through a Jupyter notebook interface, which allows it to sit inside an existing computational chemistry toolchain rather than beside it.

The best answer in this category to the question that decides many pharmaceutical software purchases, which is where the chemistry goes. Makya is offered as a SaaS platform, for implementation on customer premises, or inside the customer's own virtual private cloud, with Python package access alongside the interface. For an organization whose undisclosed structures are its most valuable asset, the on premise and private cloud options mean proprietary chemistry never has to leave the customer's control, which is a materially different risk posture from platforms reachable only by sending targets to a vendor. Explicit regional residency commitments were not located, but the deployment choice itself resolves most of what residency terms exist to address.

A genuine asymmetry sits here. Iktos is one of the few companies in this category selling a licensable SaaS product where a published rate card would be both possible and useful, yet no pricing was located, so the gap is a choice rather than a structural inevitability as it is for partnership only peers. What is disclosed is deal shape: a strategic collaboration with Servier reported at potential total value over 1 billion euros, more than 50 named collaborations, and a strategic investor base including M Ventures and the Debiopharm Innovation Fund. Dual pricing paths, software licence and discovery collaboration, are stated openly, which is more than most disclose.

Broad across therapeutic areas through more than 50 partner programmes spanning oncology, dermatology, immunology and other areas via named collaborators, but deliberately confined on modality to small molecule medicinal chemistry. The design make test integration including proprietary robotics is built for small molecule synthesis specifically. Buyers working in biologics, antibodies or nucleic acid modalities should treat this platform as out of scope rather than adaptable.